Biocon Limited · NSE:BIOCON
Biocon — Q1 FY24 Earnings Presentation
21 slides from Biocon's earnings presentation, Aug 11, 2023
Slide 1: Q1 FY24 Earnings Call
Q1 FY24 Earnings Call August 11, 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: Opening Remarks
Opening Remarks
Slide 4: Biocon Generics: Strategic Growth Pillar
Biocon Generics: Strategic Growth Pillar Execution Excellence Development Operational Quality Commercial Excellence Excellence Excellence Excellence Cost Innovation Talent Digital Leadership Focus Development Initiatives
Slide 5: Biocon Biologics: Biosimilars – Strategic Growth Pillar
Biocon Biologics: Biosimilars – Strategic Growth Pillar Portfolio Depth & Breadth Operational and organizational integration of acquired business in FY24 Excellence in R&D Tracking ahead of Plan vs. a 2-year Cost-Effective Manufacturing Transition Services Agreement Global Quality Standards 70+ coun
Slide 6: Syngene: Strategic Growth Pillar
Syngene: Strategic Growth Pillar Discovery Services Dedicated R&D Centers Development Services Manufacturing Services
Slide 7: Progressed to Integrated Reporting
Progressed to Integrated Reporting Continuously improving disclosures towards better transparency 1st GRI aligned Integrated Report for FY23 with many maiden disclosures Outcome of Gender Pay Gap Analysis Alignment with TCFD Outcome of Water Risk Assessment Outcome of Biodiversity Impact Assessment
Slide 8: Board Update
£ © Oo Q =) o i © fe} aa)
Slide 9: Board Appointments
Board Appointments Rekha Mehrotra Menon Nicolas Robert Haggar Appointed as Additional Independent Director Appointed as Additional Independent Director
Slide 10: Financial Highlights Q1 FY24
Financial Highlights Q1 FY24
Slide 11: Financial Highlights: Q1 FY24
Financial Highlights: Q1 FY24 Consolidated (in ₹ Cr.) Q1 FY24 Q1 FY23 YoY % Total Revenue 3,516 2,217 59 Biosimilars +106% | Research +25% | Generics 15% Core EBITDA1 936 661 42 Growth across Generics, Biosimilars & Research Services % Margin 28% 31% Net R&D spend at ₹315 Cr, up ₹117 Cr vs Q1 FY23,
Slide 12: Generics Q1 FY24
Generics Q1 FY24
Slide 13: Biocon Generics: Q1 FY24 Highlights
Biocon Generics: Q1 FY24 Highlights Revenue growth driven primarily by U.S. generic formulations business; new product launches in key ex-US markets In INR Cr Q1 FY24 Q1 FY23 YoY % Continued traction in immunosuppressant API portfolio Segment Revenue 700 607 15 PBT 64 63 1 Received ‘Tentative Approv
Slide 14: Biosimilars Q1 FY24
Biosimilars Q1 FY24
Slide 15: Biocon Biologics: Biosimilars – Q1 FY24 Business Update
Biocon Biologics: Biosimilars – Q1 FY24 Business Update Key Products’ Market Share1 Significant growth in market shares of key commercial products United States Jun-23 Jun-22 Fulphila (bPegfilgrastim) 16% 8% Increase in NRx to 15% for Insulin Glargine in the U.S., demonstrates Ogivri (bTrastuzumab)
Slide 16: Biocon Biologics: Biosimilars – Q1 FY24 Financial Update
Biocon Biologics: Biosimilars – Q1 FY24 Financial Update Revenues doubled Y-o-Y with driven by increased market share and In INR Cr Q1 FY24 Q1 FY23 YoY % consolidation of Viatris’ biosimilar business Revenue 2,015 977 106 Core EBITDA1 513 361 42 Sequentially, revenues largely flat due to phasing of
Slide 17: Biocon Biologics: Biosimilars – Q1 FY24 Other Updates
Biocon Biologics: Biosimilars – Q1 FY24 Other Updates Growth Catalysts Yesafili (bAflibercept) received positive opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use Growth in existing business Clinical trials for bUstekinumab and bDenosumab on track Expanded geogr
Slide 18: Research Services Q1 FY24
Research Services Q1 FY24 Syngene
Slide 19: Syngene: Q1 FY24 Update
Syngene: Q1 FY24 Update Strong performance led by Development and Manufacturing Services; supported by sustained growth in Discovery Services and the Dedicated In INR Cr Q1 FY24 Q1 FY23 YoY % Centers Revenue 808 645 25 Announced deal to acquire multimodal biologics plant from Stelis along with PBT 1
Slide 20: Concluding Remarks
Concluding Remarks
Slide 21: Q&A
Q&A